Akt expression may predict favorable prognosis in cholangiocarcinoma
- 18 September 2006
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 21 (11) , 1744-1751
- https://doi.org/10.1111/j.1440-1746.2006.04373.x
Abstract
Overexpression of signaling proteins including epidermal growth factor receptor (EGFR), Akt, mitogen activated protein kinase (MAPK) and cyclooxygenase-2 (COX-2) occurs in cholangiocarcinoma cell lines. However, the prognostic value of these markers is unknown. No prior study correlated the expression of these signaling proteins with clinical outcome. Further, co-expression of these proteins has not been reported. Co-expression may reflect cross-talk between signaling pathways. The aim of this clinicopathological study was to investigate the overexpression and co-expression of EGFR and related signaling proteins in cholangiocarcinoma and explore their relationship to clinical outcome. Twenty-four consecutive cases of cholangiocarcinoma treated from 1996 to 2002 at Roswell Park Cancer Institute were included. Immunohistochemical staining of paraffin-embedded tissue sections was performed using antibodies against Akt, p-Akt, MAPK, p-MAPK, COX-2, EGFR and p-EGFR. Two pathologists independently scored the protein expression. Cyclooxygenase-2, Akt, and p-MAPK were commonly expressed in biliary cancers (100%, 96% and 87% of malignant cells, respectively). EGFR (60%) and p-EGFR (22%) overexpression was also detected. There was a significant association between EGFR and p-EGFR (P = 0.027) and between Akt and p-Akt (P = 0.017) expression in tumor tissue. A noteworthy association was shown between MAPK and p-Akt (P = 0.054). Multivariate analysis using the Cox proportional hazard model identified the use of chemotherapy (hazard ratio [HR] = 0.039, P = 0.0002), radiation (HR = 0.176, P = 0.0441) and Akt expression (HR = 0.139, P = 0.006) as the best predictors of overall prognosis. Epidermal growth factor receptor signaling intermediates are commonly expressed in cholangiocarcinoma. Expression of Akt and use of systemic chemotherapy or radiation may correlate with improved survival.Keywords
This publication has 19 references indexed in Scilit:
- Phospho-Akt Expression Is Associated with a Favorable Outcome in Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 CasesJournal of Clinical Oncology, 2005
- Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancerInternational Journal of Cancer, 2004
- Predicting Sensitivity of Non-Small-Cell Lung Cancer to Gefitinib: Is There a Role for P-Akt?JNCI Journal of the National Cancer Institute, 2004
- Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2004
- Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocationHepatology, 2004
- Translational Regulation by P38 Mitogen–Activated Protein Kinase Signaling During Human Cholangiocarcinoma GrowthHepatology, 2003
- Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analysesJournal of Clinical Pathology, 2000
- Hilar CholangiocarcinomaAnnals of Surgery, 1998
- Simultaneous detection of epidermal growth factor receptor (EGF‐R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical methodLiver International, 1988